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Abstract
Objective: Health-related stigma is associatedwith negative psychological andquality of life outcomes in lung
cancer patients. This study describes the impact of stigma on lung cancer patients’ psychological distress and
quality of life and explores the role of social constraints and illness appraisal as mediators of effect.
Methods: A self-administered cross-sectional survey examined psychological distress and quality of
life in 151 people (59% response rate) diagnosed with lung cancer from Queensland and New South
Wales. Health-related stigma, social constraints and illness appraisals were assessed as predictors of
adjustment outcomes.
Results: Forty-nine percent of patients reported elevated anxiety; 41% were depressed; and 51%
had high global distress. Health-related stigma was significantly related to global psychological
distress and quality of life with greater stigma and shame related to poorer outcomes. These effects
were mediated by illness appraisals and social constraints.
Conclusions: Health-related stigma appears to contribute to poorer adjustment by constraining
interpersonal discussions about cancer and heightening feelings of threat. There is a need for the
development and evaluation of interventions to ameliorate the negative effects of health-related stigma
among lung cancer patients.
© 2015 The Authors. Psycho-Oncology Published by John Wiley & Sons Ltd.
Introduction
Lung cancer patients, more so than patients with other
cancers, feel stigmatized by their disease; and this increases
their subjective distress and may negatively influence help-
seeking behaviours and overall patient outcomes [1].
Stigma occurs when society labels someone as tainted on
the basis of an attribute that marks them out as different
[2]. In lung cancer, health-related stigma results from the as-
sociation between the disease and smoking and perception
© 2015 The Authors. Psycho-Oncology Published by John Wiley & Sons Ltd.
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of the disease as self-inflicted, high mortality and percep-
tions about the type of death that may be experienced [1].
Stigma is relationship and context-specific where a specific
attribute is associated with a negative evaluation that can
lead to negative discrimination and self-fulfilling prophe-
cies, stereotype activation and identity threat [3]. When
internalized, these negative evaluations lead to shame or
guilt and fear of discrimination. Stigma negatively influ-
ences social interactions and threatens an individual’s iden-
tity. Increased stress and poor coping leading to negative
mental and physical health outcomes and the amplification
of psychosocial morbidity may result from stigma [4].
A recent systematic review found that lung cancer pa-
tients consistently reported health-related stigma and that
this was related to poorer psychological and quality of life
outcomes as well as fears that medical treatment may be
futile or even denied [1]. For example, perceived stigma
is positively associated with depression in lung cancer pa-
tients and accounts for unique variance above background
demographic, clinical and psychosocial factors [5] and
also predicts poorer quality of life, again even when
significant covariates are accounted for [6]. Importantly,
this relationship persists regardless of whether the patient
has ever smoked [7].
Problematically, the mechanism by which stigma influ-
ences quality of life and psychosocial outcomes is not yet
clear. Lebel et al. found in head and neck and lung cancer
patients that the extent to which the illness was perceived
as having disrupted valued activities and interests partially
mediated the relationship between stigma and psycholog-
ical distress and subjective well-being [8]. Cataldo re-
ported that stigma was associated with lower social
support and higher social conflict, suggesting that social
interactions are implicated in the stigma–distress relation-
ship [9]. On this view, stigma about lung cancer may lead
to social isolation [10–12] and limit the patient’s ability to
discuss their cancer within their social network [13], exac-
erbating distress. A social cognitive processing model of
adjustment to cancer proposes that social constraints on
the ability to disclose trauma-related thoughts (such as
fears or concerns) have an adverse effect on patient adjust-
ment outcomes [14]. Social constraints are shaped by
social environments, and this includes norms, laws and
the media [15], which also in turn shape stigma [3]. As
well, stigma in lung cancer has been linked in qualitative
research to perceptions about treatment being futile
and death inevitable [10–12,16,17]. Thus, stigma may
heighten lung cancer patients’ negative appraisals of cancer
threat. Specifically, if a person appraises their cancer pri-
marily in a positive way, that is, as a challenge they can
meet, they would be expected to experience less distress
than a person who views their cancer predominantly as a
threat [18]. To date, researchers have not quantitatively
assessed how health-related stigma may influence these
illness appraisals.
This study describes health-related stigma, psychologi-
cal distress and quality of life in lung cancer patients and
explores social constraints, and challenge and threat ap-
praisals as potential influencing factors. We hypothesized
that health-related stigma would be related to higher psy-
chological distress and poorer quality of life and that the
effect of stigma on these adjustment outcomes would be
mediated by social constraints and challenge and threat
appraisals.
Methods
Participants
This study was conducted in Queensland (QLD) and New
South Wales (NSW), Australia (August 2012 to March
2013), with individuals newly diagnosed with lung can-
cer. Participants were recruited from respiratory clinicians,
surgeons and medical and radiation oncologists at 11 pub-
lic hospitals (six in QLD and five in NSW), and from the
Queensland Cancer Registry (QCR; a population-based
register of incident cancers). Eligible participants were
aged 18 years or over, newly diagnosed with primary in-
vasive lung cancer and able to understand English.
Recruitment procedures
Potential participants identified through direct referral
from the medical or clinical care team were provided with
a pamphlet by their clinician or a research officer that
explained the study purpose. Individuals who were inter-
ested signed a ‘permission to contact’ form and were sub-
sequently contacted by the research team to assess
eligibility and obtain consent. Recruitment through the
QCR was in two steps: first, details of the diagnosing cli-
nician were obtained from the pathology reports in the
QCR, and the clinicians were approached for permission
to contact the patient. Second, when the doctor gave
signed consent for contact, patients were mailed detailed
information about the study and consent forms inviting
them to participate. Following guidelines established by
the QCR and governed by the Public Health Act 2005,
non-responders were re-contacted if no response was re-
ceived after a further 2 weeks.
Study integrity
Ethical approval was obtained from Griffith University
Human, Gold Coast Health Service District Human and
New South Wales Population and Health Services
Research Ethics Committees. All participants provided
written consent.
Materials
Assessment included a brief 10- to 15-min computer-assisted
telephone interview (CATI) that assessed background
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sociodemographic characteristics. CATI uses a software
application that allows the interviewer to conduct a struc-
tured telephone interview with responses keyed directly into
a database at interview. Interview questions were developed
by the study team including a lung cancer clinician in consul-
tation with a lung cancer support group. On completion of
the interview, participants were mailed a self-report ques-
tionnaire that included a series of reliable and validated mea-
sures. The assessments were pilot tested with 10 participants.
Outcome variables
Psychological distress was measured using the Hospital
Anxiety and Depression Scale (HADS) [19] that measures
generalized anxiety and depression experienced during the
past week with two subscales: anxiety (HADS-A) and
depression (HADS-D) [19,20]. A cut-off of ≥8 was used
to indicate at least mild distress on each subscale, as well
as a total HADS score (HADS-T) ≥15, to indicate clini-
cally significant distress. Scale reliability was very good
(α=0.86, 0.74, 0.86). HADS has been widely used in can-
cer patients [21].
Quality of life was measured using the Functional
Assessment of Cancer Therapy-Lung (FACT-L) Scale
(version 4). The FACT-L assesses physical well-being,
social/family well-being, emotional well-being, functional
well-being and lung-cancer-specific concerns. Higher
scores indicate better quality of life [22]. Scale reliability
was excellent (α=0.92).
Predictor variables
The Cataldo Lung Cancer Stigma Scale (CLCSS) assessed
lung cancer stigma [9]. The CLCSS has four subscales
(stigma and shame, social isolation, discrimination and
smoking). Higher scores indicate greater stigma. Scale
reliability was very good: stigma and shame α=0.88,
social isolation α=0.92, discrimination α=0.85 and
smoking α=0.75.
The Social Constraints Scale measured social con-
straints on disclosure about cancer with family and friends
[15] and has been used widely in cancer populations
[23,24]. This scale assesses the degree of negative social
interactions experienced in the last 2 weeks with a partner,
close friend or relative with higher scores indicating more
constraints. Scale reliability was excellent (α=0.92)
A stress appraisal scale measured threat and challenge
appraisal as described by Roesch and Rowley [18]. These
two appraisals are considered to be primary appraisals
[25] and are most relevant to a diagnosis of cancer. A
higher score for threat appraisal indicates more threat;
higher challenge score indicates the participant feels
challenged by the diagnosis of lung cancer in a positive
way. Scale reliability was very good (α=0.82–0.84).
Statistical analysis
Multiple linear regression models applied a hierarchical
variable selection method using an a priori approach in
which the explanatory variables are entered in blocks
specified by the researcher according to logical or theoret-
ical considerations and presumed substantive priority [26].
In this approach, background sociodemographic variables
were entered first, followed by the four lung cancer stigma
subscales (shame, discrimination, social isolation and
smoking) as individual psychological variables proposed
to influence adjustment then appraisal and finally social
variables that might act as mechanisms by which stigma
influences outcomes. For each of the final regression
models, we examined the assumption of homoscedasticity
of the residuals (i.e. when there is no pattern of the resid-
uals against the fitted values) and the normality of the
residuals.
Given the number of sociodemographic variables in this
study, an iterative backward stepwise variable selection
method was first conducted for this group of variables
only. First, the sociodemographic variables of gender,
age group, recruitment method, education, private health
insurance, marital status, country of birth and lifetime his-
tory of smoking were added to the null model. Variables
were then successively excluded from the model based
on the likelihood ratio test (p≥0.2). Excluded variables
were then given the opportunity to re-enter the model at
each step (p<0.1). Once the final group of statistically
significant sociodemographic variables was determined
for each outcome measure, this group was used in the sub-
sequent hierarchical model development. Cases with any
missing values for the analysis variables were removed
from the study dataset. The amount of variance explained
by the modelled variables was estimated by the model R2.
The significance of individual variables in the final model
was assessed by the likelihood ratio test, with model coef-
ficients and their standard errors being used to generate
95% confidence intervals.
To test each of the mediation scenarios, a macro
(sgmediation.do) within the STATA software package
(Version 12.1, StataCorp LP, TX, USA) was used. This
method of quantifying the mediation pathway [27] esti-
mated the following three regression equations: (1) regress
the mediator (appraisal or social constraints) against the
independent variable (separate models for four subscales
of lung cancer stigma); (2) regress the dependent variable
(separate models for HADS-A, HADS-D and HADS-T)
on the independent variable (four subscales of stigma);
and (3) regress the dependent variable (distress) on the me-
diator and the independent variable. Mediation exists when
the association is significant in regressions (1) and (2), and
when the mediator is associated with the outcome in (3) but
the effect of the independent variable is less (i.e. the coef-
ficient is closer to zero) in equation (3) than in equation (2).
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This four-step approach does not test the significance of
the indirect pathway and has been shown to miss some real
mediation effects [28], so the indirect effect was examined
using the method of Sobel [29]. The regression coefficient
for the indirect effect represents the change in the outcome
variable (Y) for every unit change in the independent vari-
able (X) that is mediated by the mediating variable (M).
Mediation was only examined for those associations where
the total effect involving one of the stigma variables was
statistically significant.
Because of the highly skewed distribution of the indirect
effects, standard statistical tests were not considered valid.
Therefore, resampling bootstrapping was used, in which
2500 multiple random subsamples were drawn from the
study cohort. Standard errors for the indirect effect were
calculated using the results from the 2500 replications.
Results
Participants
Of the 295 patients who were approached, 199 were
contacted through the QCR and 96 through the hospital-
based clinics. Of these, 26 were deceased (15 from QCR
and 11 from clinic recruitment); 43 did not respond to
the invitation to participate (33 from QCR and 10 from
the clinics); 54 refused participation (39 from QCR and
15 from clinic recruitment); and 172 individuals
consented to participate in the study (112 from QCR and
60 from the clinics). The majority of consented partici-
pants were diagnosed with non-small-cell lung cancer
(89%), with approximately 11% diagnosed with small-cell
lung cancer. Of those who refused participation (n=54),
49% were male, and the mean age was 69 years with no
significant differences observed by method of recruitment.
Of the 172 consented patients, six died prior to the tele-
phone interview (all recruited through the QCR), six with-
drew as they were too unwell at the time of the interview
(five from QCR and one from the clinics) and two were
deemed ineligible (both from QCR) as they spoke little
English. Of the remaining 158 participants, three partici-
pants recruited through the QCR and one clinic-recruited
participant did not complete either the telephone interview
or the self-report questionnaire, while records for three
(one QCR recruitment and two clinic-recruited partici-
pants) were excluded because of incomplete responses.
Thus, the final cohort completing this cross-sectional
study consisted of 151 participants (95 through QCR re-
cruitment and 56 through clinic recruitment; 59% re-
sponse from those actually eligible), with 114 (76%)
from QLD and 37 (24%) from NSW. Participant charac-
teristics are described in Table 1. Among all 151 partici-
pants, the median time since diagnosis was 25.6 weeks,
and the mean was 29.1 weeks (standard deviation=17.5).
Half the participants (50%) had some form of private
health insurance. About 83% of participants reported that
they had smoked at least 100 cigarettes in their life
(‘lifetime history of smoking’). There were no significant
differences in sociodemographic variables between partic-
ipants recruited through the QCR and the clinics with the
exception that those recruited through the clinics were
significantly less likely to have private health insurance
(p<0.002).
Overall, 49.0% of participants were anxious (HADS-A
score≥8), and 41.1% were depressed (HADS-D score≥8).
Overall, 51.0% of participants were distressed (HADS-T
score≥15). While female participants had a higher mean
score for levels of anxiety (female participants=8.1 and
male participants=7.2), this was not significant (p=0.063).
Mean scores for depression and total distress were similar
for male and female participants (Table 2). Mean scores for
measures of distress were significantly lower for older partic-
ipants. Levels of distress were not significantly different
across categories of the other sociodemographic variables.
Overall, mean score for quality of life as measured by
FACT-L was 99.6 (standard deviation=21.6) with higher
mean scores for older people but similar scores across other
sociodemographic groups.
Effect of stigma on anxiety
Sociodemographic variables that were significantly (p<0.20)
associatedwith anxietywere age at diagnosis and gender, with
women having slightly higher levels of anxiety than men and
older people reporting lower levels of anxiety than youn-
ger people (likelihood ratio (LR) test χ2 = 16.53, df = 3,
p<0.001). Combined, these variables accounted for ap-
proximately 10% of the variance. Next, the lung cancer
stigma variables were included, and these were statisti-
cally significant (LR test χ2 = 32.72, df = 4, p<0.001),
with the model now accounting for 28% of the variance.
The impact of the stigma subscales on anxiety was limited
to stigma and shame (p=0.029) and discrimination
(p=0.018), with higher scores in these measures associated
with higher anxiety. The challenge and threat appraisal var-
iables were also statistically significant (LR test χ2=16.56,
df=2, p<0.001) when added to the model, and the model
now explained 35% of the variance. With these variables
added in, the association between anxiety and the lung can-
cer stigma subscales became statistically non-significant
(p=0.156). Finally, the social constraints variable was
added (LR test χ2=8.13, df=1, p=0.004), with the final
model explaining 39% of the variance in the HADS-A
(Table 3). In this final model, the only significant associa-
tions were between anxiety and threat appraisal (positive
association) and social constraints (positive association).
Effect of stigma on depression
Sociodemographic variables that were associated with
depression were age at diagnosis and recruitment method
1572 S. K. Chambers et al.
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(LR Test χ2 =15.35, df =3, p=0.002). Older people re-
ported lower levels of depression, while those recruited
through the clinics had slightly higher depression. This
accounted for approximately 10% of the variance. Next,
the lung cancer stigma variables were included, and model
fit improved (LR Test χ2 = 17.25, df=4, p=0.002), with
the model now accounting for 19% of the variance. How-
ever, in this model, only shame was significantly associ-
ated with depression (p=0.011), along with age group.
When the challenge and threat appraisal variables were
added, they were statistically significantly related to de-
pression (LR test χ2 =17.82, df=2, p<0.001), with the
model now explaining 28% of the variance. In this model,
the association between shame and depression was bor-
derline significant (p=0.051). Finally, the social con-
straints variable was added; however, the addition of this
variable provided no evidence of improved fit (LR test
χ2= 0.21, df=1, p=0.647). Therefore, the final model ex-
plained 28% of the variation in depression (Table 3). In
this final model, the only significant associations were be-
tween depression and age at diagnosis (older people had
lower depression), threat appraisal (positive association)
and challenge appraisal (negative association).
Effect of stigma on total distress
The only sociodemographic variable that was significantly
associated with total distress was age at diagnosis (LR test
χ2 = 19.22, df=2, p<0.001), with older people reporting
lower distress. This accounted for approximately 12% of
the variance. Next, the lung cancer stigma variables were
included, and the model fit significantly improved (LR test
χ2 = 34.79, df =4, p<0.001) accounting for 30% of the
variance. In this model, the only subscale that had an
association with total distress was stigma and shame
(p=0.004). The addition of the challenge and threat ap-
praisal variables further improved model fit (LR test
χ2 = 26.73, df=2, p<0.001), with the model now
explaining 41% of the variance. The association between
stigma and shame and distress was still statistically signif-
icant (p=0.040). Finally, the social constraints variable
was added, but was not statistically significant (LR test
χ2 = 2.41, df=1, p=0.121), so the final model explained
41% of the variation in total distress (Table 3). In this final
model, the only significant associations were between
total distress and age at diagnosis (older people had lower
distress), stigma and shame (people with higher stigma
Table 1. Mean scores for stigma, stress appraised and social constraints across sociodemographic and smoking variables (n= 151)
Stigma shame
mean (SD)a
Discrimination
mean (SD)a
Social isolation
mean (SD)a
Smoking
mean (SD)a
Challenge appraisal
mean (SD)
Threat appraisal
mean (SD)
Social constraints
mean (SD)
Sex
Male (n = 78) 15.9 (4.6) 9.3 (2.9) 12.7 (4.1) 11.0 (3.4) 3.5 (1.0) 2.6 (1.0) 1.5 (0.5)
Female (n = 73) 18.0 (6.2) 10.5 (3.6) 13.8 (4.8) 12.3 (3.5) 3.7 (0.9) 3.1 (1.0) 1.7 (0.7)
Age at diagnosis
<60 years (n = 40) 19.0 (6.2) 11.2 (3.6) 14.8 (4.3) 12.3 (3.7) 3.6 (0.9) 3.2 (1.1) 1.9 (0.7)
60–69 years (n = 69) 16.6 (5.1) 9.6 (3.2) 13.2 (4.6) 11.7 (3.3) 3.7 (1.0) 2.8 (1.0) 1.6 (0.6)
70 years and over (n=42) 15.4 (4.9) 9.1 (2.8) 11.8 (3.8) 10.8 (3.7) 3.5 (1.0) 2.6 (0.9) 1.4 (0.5)
Highest education
University/college (n=26) 18.2 (6.5) 10.1 (3.4) 13.7 (5.1) 11.7 (3.0) 3.6 (0.9) 3.0 (1.1) 1.7 (0.7)
Trade/tech/diploma
(n = 68)
17.4 (5.4) 10.3 (3.4) 13.5 (4.6) 11.5 (3.4) 3.6 (1.0) 2.9 (1.1) 1.6 (0.6)
No higher education
(n = 57)
15.8 (5.0) 9.4 (3.2) 12.6 (3.9) 11.7 (3.8) 3.7 (0.9) 2.8 (1.0) 1.6 (0.6)
Private health insurance
No (n = 76) 16.6 (5.5) 9.8 (3.6) 13.2 (4.9) 11.3 (3.7) 3.7 (1.0) 2.7 (1.1) 1.6 (0.6)
Yes (n= 75) 17.2 (5.5) 10.0 (3.1) 13.3 (4.0) 11.9 (3.3) 3.6 (1.0) 2.9 (1.0) 1.6 (0.6)
Marital status
Not married (n= 42) 16.8 (5.5) 10.4 (3.6) 14.0 (4.7) 11.6 (3.6) 3.5 (0.9) 2.9 (1.0) 1.6 (0.7)
Married/living as
married (n= 109)
17.0 (5.5) 9.7 (3.2) 12.9 (4.3) 11.6 (3.5) 3.7 (1.0) 2.8 (1.0) 1.6 (0.6)
Country of birth
Australia (n = 109) 17.1 (5.6) 10.0 (3.4) 13.3 (4.2) 11.9 (3.5) 3.7 (1.0) 2.8 (1.0) 1.6 (0.6)
Overseas (n = 42) 16.5 (5.1) 9.7 (3.2) 13.1 (5.1) 10.9 (3.4) 3.4 (0.8) 2.8 (1.0) 1.6 (0.6)
Lifetime history of smoking
Yes (n= 125) 16.9 (5.3) 9.8 (3.1) 13.2 (4.3) 11.9 (3.4) 3.6 (1.0) 2.8 (1.1) 1.6 (0.6)
No (n = 26) 17.2 (6.3) 10.4 (4.3) 13.5 (5.1) 10.2 (3.8) 3.6 (1.0) 2.8 (0.8) 1.9 (0.7)
Recruitment
Queensland Cancer
Registry (n = 95)
17.0 (5.3) 9.7 (3.1) 12.9 (4.0) 11.7 (3.4) 3.7 (1.0) 2.7 (1.0) 1.6 (0.6)
Clinic-based (n= 56) 16.8 (5.9) 10.2 (3.7) 13.7 (5.1) 11.5 (3.7) 3.5 (0.9) 3.0 (1.0) 1.7 (0.6)
SD, standard deviation.
aHigher mean scores indicate more stigma.
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and shame had higher distress), threat appraisal (positive
association) and challenge appraisal (negative association).
There was a statistically significant mediating effect for
threat appraisal and for social constraints (separately) on
the association between total distress and stigma and
shame (Table 4).
Effect of stigma on quality of life
The only sociodemographic variables that were signifi-
cantly associated with quality of life were age group at di-
agnosis and recruitment method (LR test χ2 =19.24, df=3,
p<0.001), with older people and those recruited through
the QCR reporting higher quality of life. This accounted
for approximately 12% of the variance. Next, the four lung
cancer stigma variables were included (LR test χ2 =29.76,
df =4, p<0.001), with the model now accounting for 28%
of the variance. However, of the individual subscales, in
this model, only stigma and shame had a significant associ-
ation with quality of life (p=0.010). Adding in the chal-
lenge and threat appraisal variables significantly
improved the model fit (LR test χ2 =50.75, df =2,
p<0.001), which now explained 48% of the variance.
Finally, the social constraints variable was added (LR test
χ2= 12.44, df =1, p<0.001), with the final model now
explaining 52% of the variance in quality of life (Table 3).
In this final model, the only significant associations were be-
tween quality of life and recruitment method (higher in QCR
group), stigma and shame (negative association), challenge
appraisal (positive association), threat appraisal (negative
association) and social constraints (negative association).
There was a statistically significant mediating effect for
threat appraisal and for social constraints (separately) on
the association between quality of life and stigma and
shame (Table 4).
Discussion
As in previous research [30–33], patients reported high
levels of psychological distress, again demonstrating that
lung cancer patients are highly vulnerable to psychosocial
morbidity after diagnosis. Importantly, study hypotheses
about the relationship between health-related stigma and
the outcomes of psychological distress and quality of life
were confirmed for the stigma and shame component of
lung cancer stigma. By contrast, no significant associa-
tions were found for the social isolation, discrimination
and smoking components. In brief, greater stigma and
shamewas associated with higher global distress and poorer
Table 2. Mean scores for distress, quality of life by sociodemographic and smoking variables (n= 151)
HADS – anxiety HADS – depression HADS – total Quality of life
mean (SD)
(% cases)a Mean (SD) (% cases)b Mean (SD) (% cases)c Mean (SD)
Sex
Male 42 7.2 (2.9) 40 7.1 (2.9) 46 14.3 (5.2) 101 (24)
Female 56 8.1 (3.1) 42 7.2 (2.6) 56 15.3 (4.5) 98 (19)
Age at diagnosis
<60 years 68 9.0 (3.0) 60 8.2 (2.6) 78 17.1 (4.6) 91 (22)
60–69 years 46 7.5 (3.1) 42 7.3 (2.9) 54 14.8 (4.9) 101 (21)
70 years and over 36 6.6 (2.5) 21 6.0 (2.3) 21 12.6 (3.9) 105 (21)
Highest education
University/college 46 7.8 (3.3) 54 7.7 (3.3) 50 15.5 (5.6) 100 (21)
Trade/tech/diploma 50 7.8 (3.1) 37 6.9 (2.5) 50 14.6 (4.7) 98 (23)
No higher education 49 7.4 (2.8) 40 7.3 (2.8) 53 14.6 (4.8) 101 (20)
Private health insurance
No 47 7.6 (2.7) 43 7.2 (2.8) 54 14.8 (4.6) 98 (22)
Yes 51 7.7 (3.3) 39 7.1 (2.7) 48 14.8 (5.1) 101 (21)
Marital status
Not married 55 7.8 (3.1) 40 7.3 (2.8) 52 15.1 (4.8) 98 (22)
Married/living as married 47 7.5 (3.0) 41 7.1 (2.7) 50 14.7 (4.9) 100 (22)
Country of birth
Australia 46 7.5 (3.0) 40 7.2 (2.8) 50 14.6 (4.9) 99 (21)
Overseas 57 8.0 (3.2) 43 7.1 (2.6) 52 15.1 (4.8) 100 (22)
Lifetime history of smoking
Yes 47 7.5 (3.0) 41 7.2 (2.8) 52 14.7 (4.8) 99 (22)
No 58 8.2 (3.4) 42 7.0 (2.4) 46 15.2 (5.0) 102 (20)
Recruitment
Queensland Cancer Registry (n = 95) 55 7.6 (3.2) 65 6.9 (2.7) 56 14.4 (5.1) 103.8 (21)
Clinic-based (n= 56) 45 7.7 (2.8) 48 7.7 (2.7) 38 15.4 (4.4) 92.4 (21)
SD, standard deviation.
aCase defined as score of ≥8 for the subscale of anxiety.
bCase defined as a score of ≥8 for the subscale of depression.
cCase defined as a total score of ≥15 for the total of anxiety and depression.
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quality of life. We propose that this aspect of lung-cancer-
related stigma may reflect internalized negative evaluations
[3]. There are a number of proposed pathways by which
stigma may harm health, for example, actual discrimination
andmarginalization [34] as well as internalization where the
person feels devalued as a result of the stigmatized condi-
tion. A systematic review of stigma and mental illness re-
ported a robust negative relationship between internalized
stigma and a range of psychosocial variables [35]. Specifi-
cally, if a person internalizes stigma such that it becomes
part of their world view, they may experience shame, low
self-esteem, contracted social networks and come to expect
fear and rejection, leading to a compromised quality of life
and poorer mental well-being [36]. The present findings
connecting stigma and shame to poorer outcomes are con-
sistent with this pathway.
Also consistent are the identified mediating pathways of
threat appraisal and social constraints for the effects of stigma
and shame on distress and quality of life. First, how a person
appraises their cancer in terms of being a threat or a challenge
was found to mediate the effect of stigma and shame on psy-
chological well-being and quality of life. Thus, stigma may
work, at least in part, by raising the sense of threat that the
cancer represents and lowering the person’s appraisal that
their cancer is a challenge that they can successfully cope
with. This finding supports our earlier proposal that threat ap-
praisal is a likely mechanism by which stigma effects out-
comes [1]. Consistent with the social cognitive processing
model [14] and with stigma theory [36], stigma and shame
appeared to also constrain a person’s perception that they
are able to talk about their lung cancer. From this, it would
be argued that these constraints limit that person’s ability to
obtain support as well as their opportunity to process their
cancer experience towards a sense of acceptance.
The present study did not assess what factors underpinned
the development of health-related stigma in these patients.
Previous researchers have described anti-tobacco campaigns
and negative portrayals about lung cancer as influencing stig-
matization in these patients [10,11]. Hence, efforts to over-
come health-related stigma in lung cancer may need to be
multi-level and take into account current social drivers of
stigma. Adopting a patient-centred approach, we have piloted
an acceptance-focussed psychological intervention for lung
cancer patients with acceptance strategies targeted to specific
situational cues to lung cancer stigma as well as perceptions
of self-blame about the cancer [37]. This intervention led to
meaningful improvements in psychological outcomes and de-
creases in stigma in the face of declining quality of life; how-
ever, larger efficacy trials are needed. To our knowledge, to
date, there are no other published clinical interventions
addressing stigma in lung cancer patients [1,38].
Limitations of this study include the cross-sectional de-
sign such that causality cannot be inferred. However, the
link between stigma and poorer psychological and quality
of life outcomes is consistent with previous research, and
so we suggest that our findings are robust. We note also
that the measurement of actual enacted discrimination
was beyond the scope of this study where we applied
self-reported patient outcome measurements. This is an in-
teresting area for future research where a mixed-methods
approach may prove informative. As well, only 59% of
those approached and eligible participated. Finally, data
on disease stage were not available, and so we were not
able to include this potential effect modifier. Strengths in-
clude the testing of possible mechanisms of effect and
from these new insights to inform future intervention.
These findings likely have relevance for other cancers
and chronic diseases where lifestyle factors (e.g. diet, ex-
ercise and other drug or alcohol use) are implicated and
stigma may result. Obesity is one area where it is argued
that weight stigma threatens health, generates health dis-
parities and interferes with effective intervention [39].
This is a future question for psycho-oncology and behav-
ioural and public health researchers seeking to mitigate
harm both for the well community and those who present
with or are at risk of lifestyle-related illnesses.
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Table 4. Mediating effect of threat appraisal and social constraints on global distress and quality of life
Independent
variable
Mediating
variable
% of total effect
mediated
Indirect effect (CI)a Sobel test statistics (coefficient,
standard error, p-value)
Total Distress
Shame Threat Appraisal 30.0% 0.13 (0.07–0.21) * S = 0.129 (0.035), p< 0.001
Shame Social Constraints 17.3% 0.07 (0.03–0.15) * S= 0.074 (0.027), p= 0.007
Quality of life
Shame Threat Appraisal 45.0% 0.74 (1.13 to 0.45) * S =0.745 (0.179), p< 0.001
Shame Social Constraints 29.9% 0.49 (0.96 to 0.19) * S=0.494 (0.150), p= 0.001
aCoefficient for the indirect effect, along with the bias-corrected 95% confidence interval, was calculated using bootstrapping (2500 iterations) in brackets. The indirect effect is the product
of the path (regression) coefficients between the independent variables and the mediator, and the mediator and the dependent variable.
*Bias-corrected 95% confidence interval does not include zero.
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